Table 1 Clinical information and statistics about the included 144 patients
Characteristics | Total (n %) |
|---|---|
Gender | |
 Male | 86 (59.7) |
 Female | 58 (40.3) |
Age (years) | |
 1–9 | 124 (86.1) |
 ≥ 10 | 20 (13.9) |
 Median | 4.1 |
 Range | 0.5–14.9 |
WBC (× 109/l) | |
 < 50 | 123 (85.4) |
 ≥ 50 | 21 (14.6) |
 Median | 8.3 |
 Range | 1.1–990.0 |
CNS involvement | |
 No | 143 (99.3) |
 Yes | 1 (0.7) |
Fusion gene | |
 TEL/AML1 | 30 (20.8) |
 E2A/PBX1 | 8 (5.6) |
 BCR/ABL1 | 10 (6.9) |
 MLL rearrangement | 6 (4.2) |
 Others | 2 (1.4) |
Prednisone response | |
 Good | 137 (95.1) |
 Poor | 7 (4.9) |
MRD at day 33 | |
 < 1 × 10−4 | 38 (26.4) |
 ≥ 1 × 10−4 | 106 (73.6) |
Treatment outcome | |
 Relapse | 13 (9.1) |
 Death | 11 (7.6) |
 CCR | 120 (83.3) |
Survival (%) | |
 4-year EFS | 83.1 ± 3.1 |